

123

TABLE 9-continued

Compound	Study	Dose	Dosing frequency	Survival day 28	MTD
Clomipramine	1	45 mg/kg	SID	80%	8.83
Clomipramine	2	45 mg/kg	BID	50%	9.40
Lomerizine	1	22 mg/kg	SID	30%	8.14
Sertraline	1	12 mg/kg	BID	20%	8.63

QID - every other day

SID - once daily

BID - twice daily

“+” Dosing x day after viral infection

“/” mice compared to female/male control animals

#### Other Embodiments

All publications, patent applications, and patents mentioned in this specification are herein incorporated by reference.

Various modifications and variations of the described compositions, methods, and kits of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it will be

124

understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the fields of molecular biology, medicine, immunology, pharmacology, virology, or related fields are intended to be within the scope of the invention.

What is claimed is:

- 10 **1.** A composition comprising clomiphene citrate and sertraline HCl wherein clomiphene and sertraline HCl are present in amounts that, when administered together to a patient with a filovirus-mediated disease, are effective to treat said patient.
- 15 **2.** The composition of claim **1**, wherein said filovirus is Ebola virus or Marburg virus.
- 3.** A method for treating a patient having filovirus-mediated disease, said method comprising administering to said patient a composition of claim **1** in an amount that is effective to treat said patient.
- 20 **4.** The method of claim **3**, wherein said filovirus is Ebola virus or Marburg virus.

\* \* \* \* \*